Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Cell Rep ; 40(12): 111384, 2022 09 20.
Article in English | MEDLINE | ID: mdl-36130508

ABSTRACT

Suppressive myeloid cells can contribute to immunotherapy resistance, but their role in response to checkpoint inhibition (CPI) in anti-PD-1 refractory cancers, such as biliary tract cancer (BTC), remains elusive. We use multiplexed single-cell transcriptomic and epitope sequencing to profile greater than 200,000 peripheral blood mononuclear cells from advanced BTC patients (n = 9) and matched healthy donors (n = 8). Following anti-PD-1 treatment, CD14+ monocytes expressing high levels of immunosuppressive cytokines and chemotactic molecules (CD14CTX) increase in the circulation of patients with BTC tumors that are CPI resistant. CD14CTX can directly suppress CD4+ T cells and induce SOCS3 expression in CD4+ T cells, rendering them functionally unresponsive. The CD14CTX gene signature associates with worse survival in patients with BTC as well as in other anti-PD-1 refractory cancers. These results demonstrate that monocytes arising after anti-PD-1 treatment can induce T cell paralysis as a distinct mode of tumor-mediated immunosuppression leading to CPI resistance.


Subject(s)
Biliary Tract Neoplasms , Monocytes , Humans , Biliary Tract Neoplasms/drug therapy , Biliary Tract Neoplasms/metabolism , Cytokines , Epitopes , Leukocytes, Mononuclear/metabolism , Monocytes/metabolism , Paralysis , T-Lymphocytes/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...